| Patent Number |
Title Of Patent |
Date Issued |
| RE28781 |
Carbohydrate agent of high water retention power, process of making same, and composition contai |
April 20, 1976 |
| The reaction product of a carbohydrate such as a sugar, with an alkaline agent such as an alkali metal hydroxide solution has a high water retention power which is about as high as that of the neutral skin sugar fraction obtained by extraction of the stratum corneum and far superior to |
| 6884437 |
Administration form comprising an acid-labile active compound |
April 26, 2005 |
| Novel administration forms for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration. |
| 6489327 |
Tryptase inhibitors |
December 3, 2002 |
| The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments. |
| 6436953 |
Tetrahydropyridoethers |
August 20, 2002 |
| Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases. |
| 6436952 |
Benzonaphthyridine-N-oxides comprising a PDE3 and PDE4 inhibiting activity |
August 20, 2002 |
| Compounds of the formula I, ##STR1##in which R1, R2, R3 and R4 have the meanings indicated in the description, are novel active bronchial therapeutics. |
| 6410569 |
Salt form of pantoprazole |
June 25, 2002 |
| The invention relates to the dihydrate of the magnesium salt of pantoprazole. |
| 6410551 |
Tetrazole derivatives |
June 25, 2002 |
| Compounds of formula I, ##STR1##in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are efficacious bronchial therapeutics. |
| 6395732 |
Pyrimidin-aminomethyl-pyridine derivatives, their preparation and their use in the control of he |
May 28, 2002 |
| The present invention relates to compounds of formula (I) wherein R1, R2, and R3 are hydrogen, 1-4C-alkyl, or halogen; R4, R5, R6, and R9 are hydrogen or 1-4C-alkyl; R7 and R8 are hydrogen, 1-4C-alkyl, 1-4C-alkoxy, or halogen; A is 1-7C-alkylene, 2-7C-alkenylene, 3-7C-cycloalkylene, or |
| 6384048 |
Imidazonaphthyridines |
May 7, 2002 |
| Tetrahydropyrido compounds of formula (I) ##STR1##in which the substituents have the meanings mentioned in the description, are suitable for the prevention or treatment of gastrointestinal diseases. |
| 6384047 |
Benzonaphthyridine |
May 7, 2002 |
| Compounds 8,9-diethoxy-2-methyl-6-[4(p-toluenesulfonamide) phenyl]-1,2,3,4,4a,10b-hexahydrobenzo[c][1,6]naphthyridine and 9-ethoxy-8-methoxy-2-methyl-6-[4-(p-toluenesulfonamido)phenyl]-1,2,3,4,4a, 10b-hexahydrobenzo[c][1,6]naphthyridine and medicament compositions based thereon are us |
| 6383510 |
Suppository form comprising an acid-labile active compound |
May 7, 2002 |
| Acid-labile active compounds are prepared in suppository form, particularly for rectal administration. |
| 6380196 |
Dihydrobenzofurans |
April 30, 2002 |
| Compounds of formula I, ##STR1##wherein Het represents a heterocycle having the meaning ##STR2##and R1, R2, R3 and R4 have the meanings as given in the description are novel effective bronchial therapeutics. |
| 6376485 |
Benzoxazoles with PDE-inhibiting activity |
April 23, 2002 |
| Compounds of formula I ##STR1##in which R1, R2, R3 and A have the meaning set forth in the specification, are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors useful as therapeutics in human and veterinary medicine. They are distinguished by low toxicity, good enteral a |
| 6333354 |
Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agoni |
December 25, 2001 |
| A diseased state based on acute or chronic obstruction of vessels and/or bronchi, acute or chronic inflammation and/or edema formation is advantageously treated by the combined administration of a PDE inhibitor with either an adenylate cyclase agonist or a guanylate cyclase agonist to |
| 6328993 |
Oral administration form for an acid liable active proton pump inhibitor |
December 11, 2001 |
| Novel administration form for acid-labile active compounds are described. The novel administration forms have no enteric layers and are suitable for oral administration. |
| 6315983 |
Process for the production of powdered pulmonary surfactant preparations |
November 13, 2001 |
| A powdered pulmonary surfactant preparation containing a hydrophobic protein serving as a pulmonary surfactant is obtained by spray drying an organic solution or suspension containing a hydrophobic protein serving as a pulmonary surfactant and possibly other components. Obtained power |
| 6306867 |
Imidazo- and oxazolopyridines |
October 23, 2001 |
| ##STR1##are useful for preventing or treating airway disorders, dermatoses, disorders based on excessive release of TNF and leukotrienes, disorders of the immune system and generalized inflammation in the gastrointestinal area. |
| 6303789 |
Benzamides with tetrahydrofuranyloxy substitutents as phosphodiesterase 4 inhibitors |
October 16, 2001 |
| Compounds of the formula I ##STR1##in which R1, R2, R3, R4, R5, m and n have the meanings cited in the description, are novel effective PDE-inhibitors. |
| 6303644 |
Proton pump inhibitor in therapeutic combination with antibacterial substances |
October 16, 2001 |
| The invention relates to the use of proton pump inhibitors as combination therapeutics in the treatment of bacterial diseases which do not affect the gastrointestinal track using antibacterially active compounds. |
| 6294564 |
Benzimidazoles and benzoxazoles |
September 25, 2001 |
| The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 and Y have the meanings given in the description. Said compounds are novel active bronchial therapeutic agents. |
| 6274173 |
Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
August 14, 2001 |
| An oral pharmaceutical composition comprises an acid-labile irreversible proton pump inhibitor in pellet or tablet form, wherein the irreversible proton pump inhibitor is at least partly in slow-release form. On combined administration with an anti-microbially-active ingredient, the comp |
| 6255303 |
Phthalazinone PDE III/IV inhibitors |
July 3, 2001 |
| The compounds of formula (I) in which R1, R2, R3, R4, R5, X and Y have the meanings as given in the description are novel effective bronchial therapeutica. |
| 6211203 |
Benzofuran-4-carboxamides |
April 3, 2001 |
| Compounds of formula I ##STR1##wherein R1 is 1-2C-alkoxy optionally substituted by flourine, R2 is methyl, 1-methylethyl, 3-7C-cycloalkyl or 3-7Ccycloalkylmethyl and Ar is a pyridyl which is optionally di-halo substituted. |
| 6197783 |
Tetrahydropyrido compounds |
March 6, 2001 |
| Tetrahydropyrido compounds of formula (I) ##STR1##in which the substituents have the meanings mentioned in the description, are suitable for the prevention or treatment of gastrointestinal diseases. |
| 6191138 |
Phenanthridines |
February 20, 2001 |
| Compounds of formula (I), where R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings given in the description, are new active bronchial therapeutic agents. ##STR1## |
| 6172074 |
Imidazopyridines and oxazolopyridines |
January 9, 2001 |
| Compounds of formula (I), ##STR1##wherein A, B, D, E, R1, R2, R3 and Y have the meanings cited in the description, are effective bronchial therapeutic agents. |
| 6162809 |
Pyridylthio compounds for controlling helicobacter bacteria |
December 19, 2000 |
| Pyridinylthiomethyl- and pyrimidinylthiomethyl-pyridines and their pharmacologically-acceptable compositions are useful for controlling Helicobacter bacteria and for treating those afflicted with diseases based on Helicobacter bacteria. |
| 6160119 |
Fused dihydropyrans |
December 12, 2000 |
| Compounds of formula (I) in which the substituents have the meanings mentioned in the specification, are suitable for the prevention and treatment of gastrointestinal diseases. ##STR1## |
| 6143759 |
Tetrazoles |
November 7, 2000 |
| Compounds of formula (I) in which R.sup.4 is a phenyl radical substituted by R.sup.5, where R.sup.5 is a tetrazole-5-yl-radical optionally substituted by a radical R.sup.6, are novel efficacious PDE3/4 inhibitiors. |
| 6132768 |
Oral pharmaceutical composition with delayed release of active ingredient for reversible proton |
October 17, 2000 |
| An oral pharmaceutical composition of a reversible proton pump inhibitor in pellet or tablet form, wherein the reversible proton pump inhibitor is at least partly in slow-release form, is distinguished, on combined administration with an antimicrobially-active ingredient, by an enhanced |
| 6127378 |
Phenanthridines substituted in the 6 position |
October 3, 2000 |
| Compounds of the formula I in which R1, R2, R3, R31, R4, R5, R51 and R6 have the meanings indicated in the description, are novel efficacious bronchial therapeutics. |
| 6124313 |
Imidazopyridine azolidinones |
September 26, 2000 |
| Imidazopyridine-azolidinones are useful for treating or preventing amenable gastro-intestinal ailments. |
| 6121279 |
Substituted 6-phenylphenanthridines |
September 19, 2000 |
| The invention relates to compounds of formula (I): wherein R1, R2, R3, R31, R4, R5, R51 and R6 are as defined in the specification. The compounds are phosphodiesterase inhibitors. Also disclosed are pharmaceutical compositions and methods of use of the compounds. |
| 6121274 |
Dihydrobenzofurane |
September 19, 2000 |
| The invention concerns componuds of formula (I), in which R1, R2, R3 and R4 have the meanings given in the description. The compounds are novel, effective PDE-inhibitors. |
| 6120752 |
Medicinal aerosol products containing formulations of ciclesonide and related steroids |
September 19, 2000 |
| A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including an anti-inflammatory steroid of the formula ##STR1## in which: R.sub.1 is 1-butyl, 2-butyl, cyclohexyl or phenyl andR.sub.2 is acetyl or isobutanoyl, in particular ciclesonide. The formulations a |
| 6107312 |
Thiopyridines for use in the control of helicobacter bacteria |
August 22, 2000 |
| Thiopyridines of formula (I) ##STR1## in which the substituents and symbols are as defined in the specification are suitable for use in controlling Helicobacter bacteria. They are compounded into medicament compositions and administered to subjects afflicted with a disease based |
| 6103718 |
Phthalazinones |
August 15, 2000 |
| Compounds of formula I wherein R1, R2, R3, R4 and R5 have the means set forth in the description are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (specifically of type 4), which are effective bronchial therapeutics. |
| 6096758 |
3-methylimidazopyridines |
August 1, 2000 |
| The invention relates to certain substituted imidazo[1,2-a]pyridines useful in the treatment of gastro-intestinal disorders. |
| 6080782 |
Cyclohexyl dihydrobenzofuranes |
June 27, 2000 |
| Compounds of formula I are selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (namely of type IV). They and pharmaceutical compositions in which they are active ingredients are useful as bronchial therapeutics, for elimination of erectile dysfunction and for treatment of diso |
| 6054475 |
Substituted dihydrobenzofuran-based phosphodiesterase 4 inhibitors useful for treating airway di |
April 25, 2000 |
| Compounds of formula (I) ##STR1## and the salts of these compounds, are efficacious PDE (phosphodiesterase) inhibitors. |
| 6046329 |
Uracil derivatives |
April 4, 2000 |
| Compounds of formula I, in which the substituents and symbols have the meanings indicated in the description, R5-HT.sub.1A -agonists and .alpha..sub.1 -adrenoceptor blockers. Compositions containing these compounds as active ingredients are useful for treating those diseases which ca |
| 6043263 |
(2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors |
March 28, 2000 |
| The invention relates to compounds of the formula (I), wherein R1, R2, R3, R4, R5 and n have the meanings cited in the description said compounds being new effective bronchial therapeutic agents. |
| 6043242 |
Imidazopyridazines |
March 28, 2000 |
| Compounds of formula (I) ##STR1## in which the substituents and symbols have the meanings indicated in the description, are suitable for controlling Helicobacter bacteria. |
| 6020340 |
Imidazopyridines |
February 1, 2000 |
| Compounds of formula I wherein one of A and B is a nitrogen atom and the other is CH, and Ar has one of the meanings stated in the specification, are effective bronchial therapeutics and are also useful for treating dermatoses. These compounds are synthesized and formed into medicament |
| 6011037 |
Thiazole derivatives with phosphodiesterase-inhibiting action |
January 4, 2000 |
| Compounds having the formula (I): ##STR1## wherein R1, R2, R3, R4, R5 and n have the meanings given in the description. The compounds of formula (I) are selective inhibitors of phosphodiesterase IV. |
| 6008215 |
Benzonaphthyridines as bronchial therapeutics |
December 28, 1999 |
| Compounds of formula (I) in which R1, R2, R3 and R4 have the meanings indicated in the description, are novel active bronchial therapeutics |
| 5997903 |
Oral-administration forms of a medicament containing pantoprazol |
December 7, 1999 |
| The invention relates to oral presentation forms for pantoprazole, which consist of a core, an intermediate layer and an outer layer which is resistant to gastric juice. |
| 5994369 |
Substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders |
November 30, 1999 |
| The invention concerns the use of compounds of formula (I), in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m and n have the meanings indicated herein for use in the treatment of sigma-receptor modulated disorders. ##STR1## |
| 5981184 |
Screening kit and process for determining action of substances inhibiting the P-type ATPase acti |
November 9, 1999 |
| A screening-model is disclosed for determining the inhibiting effect of substances on the P-type ATP-ase activity of Helicobacter. The screening model in question comprises: (a) a recombinant organism consisting of host cells transformed with at least one P-type ATP-ase gene which can be |
| 5942409 |
Process for identification of substances modulating ureI dependent mechanisms of Helicobacter py |
August 24, 1999 |
| The present invention provides a screening process for the identification of anti-helicobactericidal substances modulating ureI dependent mechanisms of gastric Helicobacter metabolism. Gastric Helicobacter cells are treated with a substance to be tested for modulating ureI dependent mech |
